Biopure Appoints Allan Ferguson to Its Board of Directors.CAMBRIDGE, Mass., April 9 /PRNewswire-FirstCall/ -- Biopure Corporation today announced the appointment of Allan Ferguson to the company's board of directors. He brings to the board over 25 years of operating and management experience in engineering, manufacturing, and research and development, and 20 years of experience in international venture capital investing with life science and technology companies. Ferguson is also a director of Autoimmune Inc., TransMedics Inc., Ulthera Inc., Xthetix Inc., and ZONARE Medical Systems. He recently retired as a senior partner of 3i's Venture Capital Group, where he headed up the firm's U.S. operation that he helped start. He previously served as a Biopure board member from December 1988 to December 1990, in connection with 3i's investment in the company. Ferguson was formerly a managing partner of Aspen Ventures and a general partner of Atlas Ventures, where he helped establish Atlas' healthcare practice. He has also held senior operating positions at Johnson & Johnson, Ortho Diagnostics Systems Inc. and Damon Biotech, where he served as a managing director and senior vice president responsible for European operations. Ferguson is a member of the New England New England, name applied to the region comprising six states of the NE United States—Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and Connecticut. The region is thought to have been so named by Capt. Venture Capital Association (NEVCA) and the National Association of Corporate Directors (NACD NACD National Association of Corporate Directors NACD National Association of Conservation Districts NACD National Association of Chemical Distributors NACD National Academy for Child Development NACD National Advisory Committee on Drugs ), and was previously a board member of the National Venture Capital Association (NVCA NVCA National Venture Capital Association ). He holds a B.S. in chemical engineering from the University of Delaware [3] The student body at the University of Delaware is largely an undergraduate population. Delaware students have a great deal of access to work and internship opportunities. and attended the Harvard Executive Management program. About Biopure Corporation Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa South Africa, Afrikaans Suid-Afrika, officially Republic of South Africa, republic (2005 est. pop. 44,344,000), 471,442 sq mi (1,221,037 sq km), S Africa. for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for a potential indication in cardiovascular ischemia Ischemia Definition Ischemia is an insufficient supply of blood to an organ, usually due to a blocked artery. Description Myocardial ischemia is an intermediate condition in coronary artery disease during which the heart tissue is , in addition to supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Oxyglobin is indicated for the treatment of anemia in dogs, and has been used to treat an estimated 100,000 animals to date.
Contact: Douglas Sayles Herb Lanzet (Investors)
Biopure Corporation H.L. Lanzet Inc.
(617) 234-6826 (212) 888-4570
IR@biopure.com lanzet@aol.com
CONTACT: Douglas Sayles, Biopure Corporation, +1-617-234-6826, IR@biopure.com; investors, Herb Lanzet, H.L. Lanzet Inc., +1-212-888-4570, lanzet@aol.com Web site: http://www.biopure.com/ |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion